Full Press Release Details
Menlo Park, California, December 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today that Chief Executive Officer, Merdad Parsey, M.D., Ph.D., will present at the 25th Annual Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 9:10 AM EST at the Crowne Plaza Times Square in New York, New York.
About 3-V Biosciences 3-V Biosciences, Inc. is a discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company’s lead candidate TVB-2640 is an oral fatty acid synthase (FASN) inhibitor that induces tumor cell apoptosis by interfering with tumor cell metabolism and blocking oncogenic signaling pathways. TVB-2640 is initiating Phase 1b expansion cohorts for the treatment of solid tumors, including colorectal and non-small cell lung cancers. 3-V’s antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, with a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.
Contact Information Merdad Parsey, M.D., Ph.D. Chief Executive Officer 650-561-8600
Media Inquiries BCC Partners on behalf of 3-V Biosciences, Inc. Karen L. Bergman 650-575-1509 kbergman tners.com